Taking appropriate measures to decrease the expression of IL-17 or prevent it from binding to the receptor to reduce the symptoms of RA and decrease the possibility of atherosclerosis may be a feasible direction for treating RA complicated with cardiovascular disease. This evidence concerns the gene IL17A and cardiovascular disorder.